High Circulating Caspase-Cleaved Keratin 18 Fragments (M30) Indicate Short-Term Mortality in Critically Ill Patients

Alexander Koch, Eray Yagmur, Janine Linka, Fabienne Schumacher, Jan Bruensing, Lukas Buendgens, Ulf Herbers, Ger H. Koek, Ralf Weiskirchen, Christian Trautwein, Frank Tacke*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Caspase-cleaved fragments of the intermediate filament protein keratin 18 (cytokeratin-18 (CK18)) can be detected in serum as M30 levels and may serve as a circulating biomarker indicating apoptosis of epithelial and parenchymal cells. In order to evaluate M30 as a biomarker in critical illness, we analyzed circulating M30 levels in 243 critically ill patients (156 with sepsis, 87 without sepsis) at admission to the medical intensive care unit (ICU), in comparison to healthy controls (n = 32). M30 levels were significantly elevated in ICU patients compared with healthy controls. Circulating M30 was closely associated with disease severity but did not differ between patients with sepsis and ICU patients without sepsis. M30 serum levels were correlated with biomarkers of inflammation, cell injury, renal failure, and liver failure in critically ill patients. Patients that died at the ICU showed increased M30 levels at admission, compared with surviving patients. A similar trend was observed for the overall survival. Regression analyses confirmed that M30 levels are associated with mortality, and patients with M30 levels above 250.8 U/L displayed an excessive short-term mortality. Thus, our data support the utility of circulating levels of the apoptosis-related keratin fragment M30 as a prognostic biomarker at ICU admission.
Original languageEnglish
Article number8583121
Number of pages8
JournalDisease Markers
Volume2018
DOIs
Publication statusPublished - 1 Jan 2018

Keywords

  • CELL-DEATH
  • PREDICTS MORTALITY
  • THERAPEUTIC TARGET
  • CRITICAL ILLNESS
  • SEPSIS
  • APOPTOSIS
  • PATHOGENESIS
  • SURVIVAL
  • LIVER
  • SHOCK

Cite this